Prescription patterns of ranitidine in Canada (Q20-12)

Prescription patterns of ranitidine in Canada (Q20-12)

Prescription patterns of ranitidine in Canada (Q20-12)

Q20-12

Overview

What are the objectives?
  • The objectives are to characterize the use of dispensed H2RAs in Canada by describing demographic and clinical characteristics of users and prescribers and by quantifying rates of use and population exposures.

Manuscripts

Levy AR, Stock D, Paterson JM, Tamim H, Chateau D, Quail J, Ronksley PE, Carney G, Reynier P, Targownik L, for the Canadian Network for Observational Drug Effect Studies (CNODES). Prescription ranitidine use and population exposure in 6 Canadian provinces, 1996 to 2019: a serial cross-sectional analysis. CMAJ Open. 2023;11(6):E1033-E1040.

Presentations

Project Team

Project Lead
Adrian Levy PhD
Methods Lead
David Stock PhD
Content Expert
Laura Targownik
Steering Committee Liaison
Michael Paterson MSc
Research Assistant
Carolina Moriello MSc
Site Investigator
Jacques LeLorier MD, MSc, FRCPC, FISPE
Quebec
Site Investigator
Jacqueline Quail PhD
Saskatchewan
Site Investigator
Michael Paterson MSc
Ontario
Site Investigator
Paul Ronksley PhD
Alberta
Site Investigator
Greg Carney BSc, PhD
British Columbia
Site Investigator
Dan Chateau PhD
Manitoba
Analyst
Xinya Lu PhD
Saskatchewan
Analyst
Fangyun Wu MSc
Ontario
Analyst
David Stock PhD
Atlantic
Analyst
Matthew Dahl BSc
Manitoba